Related Experiment Videos
Dieldrin-induced mallory bodies in hepatic tumors of mice of different strains
Abstract:
Mallory bodies (MBs) were induced in hepatic tumors by administration for up to 85 weeks of a diet containing 10 ppm dieldrin to 50 C3H/He and 62 C57BL/6J x C3H/He B6C3F1 male mice. MBs were seen in 15 of 28 (54%) mice which developed benign hepatic tumors and 33 of 45 (73%) mice with hepatocellular carcinoma, but in only 3 of 39 (8%) mice without hepatic tumors. In mice with tumors, the MBs were predominantly confined to tumor tissue and persisted in a carcinoma transplanted into a nude mouse. MBs were not observed, however, in hepatic tumors of 67 C57BL/6J, 49 C3H/He, or 81 B6C3F1 mice given 12 micrograms diethylnitrosamine i.p. on Days 0, 3, 9, and 15. Thirty-one of 195 control mice of all three strains had hepatic tumors. Only one of the controls had a tumor with an MB, and no MBs were seen in nontumor-bearing livers of controls animals. These observations, coupled with the results of a previous study in which MBs were observed in hepatocytes of dieldrin-treated C57BL/6J mice, indicate that mice treated with dieldrin are a reliable animal model for the study of MBs.
Insights
Dieldrin administration reliably induced Mallory bodies (MBs) in mouse liver tumors, establishing a valuable animal model for studying these hepatic cellular inclusions.
Area of Science:
- Hepatology
- Toxicology
- Carcinogenesis
Background:
- Mallory bodies (MBs) are intracellular protein aggregates found in various liver diseases.
- Understanding the mechanisms of MB formation is crucial for diagnosing and treating liver pathologies.
Purpose of the Study:
- To investigate the potential of dieldrin as an inducer of Mallory bodies in mouse liver tumors.
- To evaluate the utility of dieldrin-induced MBs in a murine model for further research.
Main Methods:
- Male B6C3F1 mice were fed a diet containing 10 ppm dieldrin for up to 85 weeks.
- Hepatic tumors and MBs were assessed histologically.
- MBs were also examined in transplanted tumors and compared to diethylnitrosamine-induced tumors.
Main Results:
- Dieldrin administration significantly increased the incidence of MBs in mice with hepatic tumors (54% benign, 73% carcinoma) compared to those without tumors (8%).
- MBs were primarily located within tumor tissues and persisted after tumor transplantation.
- MBs were not observed in diethylnitrosamine-induced hepatic tumors or in control mice.
Conclusions:
- Dieldrin is an effective agent for inducing MBs in mouse liver tumors.
- Dieldrin-treated mice represent a reliable animal model for studying Mallory bodies.
- This model can facilitate research into the pathogenesis and potential therapeutic strategies for MB-associated liver conditions.